[Comment] Deep and durable lipoprotein(a) lowering: Kylo-11 advances RNA interference therapeutics

Summary

The Lancet publishes a comment on Kylo-11, an RNA interference therapeutic for reducing lipoprotein(a) levels in patients at risk for atherosclerotic cardiovascular disease and aortic valve stenosis. The article discusses clinical evidence supporting the causal association between lipoprotein(a) and cardiovascular risk.